Phenylethanoic acid, phenylpropanoic acid and phenylpropenoic acid conjugates and prodrugs of hydrocodone, method of making and use thereof

ABSTRACT

The presently described technology provides phenylethanoic acid, phenylpropanoic acid, phenylpropenoic acid, a salt thereof, a derivative thereof or a combination thereof chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs or compositions of hydrocodone which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.

RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No.12/828,456, filed Jul. 1, 2010, which claims priority to and benefit ofU.S. provisional application No. 61/222,730, filed Jul. 2, 2009, both ofwhich are herein incorporated by reference in their entireties.

FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

[Not Applicable]

BACKGROUND OF THE INVENTION

Opioids are highly effective as analgesics and are commonly prescribedfor the treatment of acute and chronic pain. They are also commonly usedas antitussives. The opioids, however, also produce euphoria and arehighly addictive. As a result they are often abused with far reachingsocial and health related consequences.

Because of the inherent potential for abuse, it is desirable that anypharmaceutical composition containing an opioid agonist be made asabuse-resistant or abuse-deterrent as practical. Illicit users oftenwill attempt to circumvent the extended release properties of thesedosage forms by injecting or otherwise misusing the product in order toachieve an immediate release of the opioid agonist.

Despite their addictive properties and the potential for abuse,morphine-like drugs, particularly, codeine, hydrocodone, and oxycodonehave been routinely prescribed as treatment for severe acute and chronicpain in recent decades. This is, in part, because there are noalternatives to relieve severe pain that is resistant to abuse potentialexcept other less potent analgesics such as non-steroidalanti-inflammatory drugs (NSAIDS). In this regard, there has been work todecrease the abuse potential. Thus far, approaches taken, unfortunately,have not solved the problem. Therefore there is still a need fordrug-abuse resistant compositions.

Hydrocodone is an opioid analgesic and antitussive and occurs as fine,white crystals or as crystalline powder. Hydrocodone is a semisyntheticnarcotic analgesic prepared from codeine with multiple actionsqualitatively similar to those of codeine. It is mainly used for reliefof moderate to moderately severe pain. Additionally, it is used as anantitussive in cough syrups and tablets in sub-analgesic doses (2.5-5mg).

Patients taking opioid analgesics such as hydrocodone for pain reliefcan become unintentionally addicted. As tolerance to the opioidsdevelops, more drug is needed to alleviate the pain and generate thesense of well being initially achieved with the prescribed dose. Thisleads to dose escalation, which if left unchecked can lead rapidly toaddiction. In some cases patients have become very addicted in as littleas thirty days.

BRIEF SUMMARY OF THE INVENTION

The present technology utilizes covalent conjugation of the opioidhydrocodone with certain aryl carboxylic acids to decrease its potentialfor causing overdose or abuse, by requiring the active hydrocodone to bereleased through enzymatic or metabolic breakdown of the conjugate invivo. The present technology also provides methods of deliveringhydrocodone as conjugates that release the hydrocodone following oraladministration while being resistant to abuse by circuitous routes suchas intravenous (“shooting”) injection and intranasal administration(“snorting”).

The presently described technology in at least one aspect provides aslow or sustained or controlled release composition of conjugatedhydrocodone that allows slow or sustained or controlled delivery of thehydrocodone and/or its active metabolite, hydromorphone, into the bloodsystem of a human or animal within a safe therapeutic window upon, forexample, oral administration. At least some compositions andformulations of the current technology can lessen addiction, abusepotential and/or other common side effects associated with hydrocodoneand similar compounds.

In one aspect, the present technology provides a composition comprisingat least one conjugate of hydrocodone and at least one of phenylethanoicacid, phenylpropanoic acid, phenylpropenoic acid, a salt thereof, aderivative thereof or a combination thereof.

In another aspect, the present technology provides a compositioncomprising at least one phenylethanoic acid, a salt thereof, aderivative thereof or a combination thereof having the formula I:

wherein, X, Y and Z are independently selected from the group consistingof H, O, S, NH and —(CH₂)_(x)—; R¹, R² and R³ are independently selectedfrom the group consisting of H, alkyl, alkoxy, aryl, alkenyl, alkynyl,halo, haloalkyl, alkylaryl, arylalkyl, heterocycle, aromatic,arylalkoxy, cycloalkyl, cycloalkenyl and cycloalkynyl; o, p, q areindependently selected from 0 or 1; x is an integer between 1 and 10;Alk is an alkyl chain —(CH₂)_(n)— wherein n is 0 or 1; and R⁶ is H, OHor carbonyl. In some aspects, the phenylethanoic acid is profen ortyrosine metabolite.

In another aspect, the present technology provides a compositioncomprising at least one conjugate of hydrocodone and at least onephenylethanoic acid, phenylpropanoic acid, phenylpropenoic acid, a saltthereof, a derivative thereof or a combination thereof, wherein thephenylpropenoic acid, phenylpropanoic acid, a salt thereof, a derivativethereof or a combination thereof having the formula II or formula III:

wherein, X, Y and Z are independently selected from the group consistingof H, O, S, NH and —(CH₂)_(x)—; R¹, R² and R³ are independently selectedfrom the group consisting of H, alkyl, alkoxy, aryl, alkenyl, alkynyl,halo, haloalkyl, alkylaryl, arylalkyl, heterocycle, aromatic,arylalkoxy, cycloalkyl, cycloalkenyl and cycloalkynyl; o, p, q areindependently selected from 0 or 1; x is an integer between 1 and 10; R⁴is H or OH; and R⁵ is H, OH or carbonyl.

In some aspects, the prodrug or hydrocodone conjugate of the presenttechnology is a phenylethanoate-hydrocodone conjugate,phenylpropanoate-hydrocodone conjugate, or aphenylpropenoate-hydrocodone conjugate.

In some aspects, the prodrug or hydrocodone conjugate of the presenttechnology is ibuprofen-hydrocodone, cinnamate-hydrocodone ornaproxen-hydrocodone.

In one aspect of the present technology, the prodrug or hydrocodoneconjugate of the present technology is used to treat narcotic or opioidabuse or prevent opioid withdrawal.

In another aspect of the present technology, the prodrug or hydrocodoneconjugate of the present technology is used to treat pain.

In another aspect of the present technology, the prodrug or hydrocodoneconjugate of the present technology is used to treat moderate to severepain.

In another aspect of the present technology, the prodrug or hydrocodoneconjugate of the present technology reduces or prevents oral, intranasalor intravenous drug abuse.

In another aspect of the present technology, the prodrug or hydrocodoneconjugate of the present technology provides oral, intranasal orparenteral drug abuse resistance.

In another aspect of the present technology, the prodrug or hydrocodoneconjugate of the present technology provides a slower rate of releaseover time and a substantially equivalent AUC when compared to a molarequivalent amount of unconjugated hydrocodone over that same timeperiod.

In another aspect of the present technology, the prodrug or hydrocodoneconjugate of the present technology exhibits less variability in theoral PK profile when compared to unconjugated hydrocodone.

In another aspect, the prodrug or hydrocodone conjugate of the presenttechnology has reduced side effects when compared with unconjugatedhydrocodone.

In another aspect, the prodrug or hydrocodone conjugate of the presenttechnology prevents drug tampering by either physical or chemicalmanipulation.

In another aspect, the prodrug or hydrocodone conjugate of the presenttechnology is provided in an amount sufficient to provide atherapeutically bioequivalent AUC when compared to a molar equivalent ofunconjugated hydrocodone. In other aspects of the present technology,the prodrug or hydrocodone conjugate is provided in an amount sufficientto provide a therapeutically bioequivalent AUC when compared tounconjugated hydrocodone but does provide a lower C_(max) or does notprovide a C_(max) spike. In yet another aspect, the prodrug orhydrocodone conjugate is provided in an amount sufficient to provide atherapeutically bioequivalent AUC when compared to unconjugatedhydrocodone, but does not provide an equivalent C_(max) spike (forexample, has a lower C_(max)). In some aspects, at least one conjugateprovides a therapeutically bioequivalent C_(max) when compared tounconjugated hydrocodone.

In another aspect of the present technology, the prodrug or hydrocodoneconjugate exhibits less variability in the intranasal PK profile whencompared to unconjugated hydrocodone. In yet another aspect, the prodrugor hydrocodone conjugate exhibits less variability in the parenteral PKprofile when compared to unconjugated hydrocodone. In yet a furtheraspect, the prodrug or hydrocodone conjugate exhibits less variabilityin the intravenous PK profile when compared to a molar equivalent ofunconjugated hydrocodone.

In a further aspect, the present technology provides a method fortreating a patient having a disease, disorder or condition requiringbinding of an opioid to the opioid receptors of the patient, comprisingorally administering to the patient a pharmaceutically effective amountof at least one conjugate of hydrocodone and at least one ofphenylethanoic acid, phenylpropanoic acid, phenylpropenoic acid, a saltthereof, a derivative thereof or a combination thereof.

In another aspect, the present technology provides a method for treatinga patient having a disease, disorder or condition requiring or mediatedby binding of an opioid to the opioid receptors of the patient,comprising orally administering to the patient a pharmaceuticallyeffective amount of at least one conjugate of hydrocodone and at leastone of phenylethanoic acid, phenylpropanoic acid, phenylpropenoic acid,wherein the conjugate of hydrocodone is ibuprofen-hydrocodone,cinnamate-hydrocodone or naproxen-hydrocodone.

In another aspect, the present technology provides a method for treatinga patient having a disease, disorder or condition requiring inhibitingbinding of an opioid to the opioid receptors of the patient, comprisingorally administering to the patient a pharmaceutically effective amountof at least one conjugate of hydrocodone and at least one ofphenylethanoic acid, phenylpropanoic acid, phenylpropenoic acid, a saltthereof, a derivative thereof or a combination thereof.

In yet another aspect, the present technology provides a method fortreating a patient having a disease, disorder or condition requiringinhibiting binding of an opioid to the opioid receptors of the patient,comprising orally administering to the patient a pharmaceuticallyeffective amount of at least one conjugate of hydrocodone and at leastone of phenylethanoic acid, phenylpropanoic acid, phenylpropenoic acid,a salt thereof, a derivative thereof or a combination thereof, whereinthe conjugate is ibuprofen-hydrocodone, cinnamate-hydrocodone, ornaproxen-hydrocodone.

In yet another aspect, the present technology provides a pharmaceuticalkit comprising a specified amount of individual doses in a packagecontaining a pharmaceutically effective amount of at least one conjugateof hydrocodone and at least one of phenylethanoic acid, phenylpropanoicacid, phenylpropenoic acid, a salt thereof, a derivative thereof or acombination thereof.

In some aspects, the present technology provides a pharmaceutical kitincluding a conjugate of hydrocodone and at least one phenylethanoicacid, a salt thereof, a derivative thereof or a combination thereofhaving the formula I:

wherein, X, Y and Z are independently selected from the group consistingof H, O, S, NH and —(CH₂)_(x)—; R¹, R² and R³ are independently selectedfrom the group consisting of H, alkyl, alkoxy, aryl, alkenyl, alkynyl,halo, haloalkyl, alkylaryl, arylalkyl, heterocycle, aromatic,arylalkoxy, cycloalkyl, cycloalkenyl and cycloalkynyl; o, p, q areindependently selected from 0 or 1; x is an integer between 1 and 10;Alk is an alkyl chain —(CH₂)_(n)—, wherein n is 0 or 1; and R⁶ is H, OHor carbonyl.

In another aspect, the present technology provides a pharmaceutical kitincluding a conjugate of hydrocodone and at least one of phenylpropenoicacid, phenylpropanoic acid, a salt thereof, a derivative thereof or acombination thereof having the formula II or formula III:

wherein, X, Y and Z are independently selected from the group consistingof H, O, S, NH and —(CH₂)_(x)—; R¹, R² and R³ are independently selectedfrom the group consisting of H, alkyl, alkoxy, aryl, alkenyl, alkynyl,halo, haloalkyl, alkylaryl, arylalkyl, heterocycle, aromatic,arylalkoxy, cycloalkyl, cycloalkenyl and cycloalkynyl; o, p, q areindependently selected from 0 or 1; x is an integer between 1 and 10; R⁴is H or OH; and R⁵ is H, OH or carbonyl.

In some aspects, the kit includes instructions for use of the kit in amethod for treating or preventing drug withdrawal symptoms or pain in ahuman.

In yet another aspect, the present technology provides a prodrugcomprising at least one phenylethanoate hydrocodone conjugate, a saltthereof, a derivative thereof or a combination thereof, wherein thephenylethanoate is derived from phenylethanoate acid having the formulaI:

wherein, X, Y and Z are independently selected from the group consistingof H, O, S, NH and —(CH₂)_(x)—; R¹, R² and R³ are independently selectedfrom the group consisting of H, alkyl, alkoxy, aryl, alkenyl, alkynyl,halo, haloalkyl, alkylaryl, arylalkyl, heterocycle, aromatic,arylalkoxy, cycloalkyl, cycloalkenyl and cycloalkynyl; o, p, q areindependently selected from 0 or 1; x is an integer between 1 and 10;Alk is an alkyl chain —(CH₂)_(n)—, wherein n is 0 or 1; and R⁶ is H, OHor carbonyl.

In another aspect, the present technology provides a prodrug comprisingat least one phenylpropanoate hydrocodone conjugate, phenylpropenoatehydrocodone conjugate, a salt thereof, a derivative thereof or acombination thereof, wherein the phenylpropanoate or phenylpropenoate isof formula II or formula III:

wherein, X, Y and Z are independently selected from the group consistingof H, O, S, NH and —(CH₂)_(x)—; R¹, R² and R³ are independently selectedfrom the group consisting of H, alkyl, alkoxy, aryl, alkenyl, alkynyl,halo, haloalkyl, alkylaryl, arylalkyl, heterocycle, aromatic,arylalkoxy, cycloalkyl, cycloalkenyl and cycloalkynyl; o, p, q areindependently selected from 0 or 1; x is an integer between 1 and 10; R⁴is H or OH; and R⁵ is H, OH or carbonyl.

In some aspects, the present technology provides a prodrug comprisingibuprofen-hydrocodone.

In other aspects, the present technology provides a prodrug comprisingcinnamate-hydrocodone.

In other aspects, the present technology provides a prodrug comprisingnaproxen-hydrocodone.

BRIEF DESCRIPTION OF SEVERAL VIEWS OF THE DRAWINGS

FIGS. 1A and 1B. Structures of some phenylethanoic acids and derivativesfor use in making the conjugates of the present technology.

FIG. 2. Structures of some phenylpropanoic acids and derivatives for usein making the conjugates of the present technology.

FIG. 3. Structures of some phenylpropenoic acids and derivatives for usein making the conjugates of the present technology.

FIGS. 4A and 4B. Common hydrocodone products and dosage ranges.

FIG. 5. Plasma concentrations of hydrocodone released from Ibu-HC andDiglycolate-HC over time upon oral administration in rats.

FIG. 6. Plasma concentrations of active metabolite hydromorphone overtime upon oral administration of Ibu-HC and Diglycolate-HC in rats.

FIG. 7. Plasma concentrations of hydrocodone released from Ibu-HC andAdipate-HC over time upon intranasal administration in rats.

FIG. 8. Plasma concentrations of active metabolite hydromorphone overtime upon intranasal administration of Ibu-HC and Adipate-HC in rats.

FIG. 9. Plasma concentrations of hydrocodone released from Ibu-HC,Cinnamate-HC and Hydrocodone•BT over time upon oral administration inrats.

FIG. 10. Plasma concentrations of active metabolite hydromorphone overtime upon oral administration of Ibu-HC, Cinnamate-HC and Hydrocodone•BTin rats.

FIG. 11. Plasma concentrations of hydrocodone released from Ibu-HC andHydrocodone•BT over time upon intranasal administration in rats.

FIG. 12. Plasma concentrations of active metabolite hydromorphone overtime upon intranasal administration of Ibu-HC and Hydrocodone•BT inrats.

FIG. 13. Synthesis of exemplary conjugate compounds of the presenttechnology. FIG. 13A. Synthesis of Hydrocodone-ibuprofen. FIG. 13B.Synthesis of cinnamic acid ester of hydrocodone.

DETAILED DESCRIPTION OF THE INVENTION

The present technology provides compositions comprising aryl carboxylicacids chemically conjugated to hydrocodone (morphinan-6-one,4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs andcompositions of hydrocodone. In some embodiments, the chemical bondbetween these two moieties can be established by reacting the C-6 enoltautomer of hydrocodone with the carboxylic acid function of an arylcarboxylic acid thereby creating an enol-ester conjugate.

The use of “opioid” is meant to include any drug that activates theopioid receptors found in the brain, spinal cord and gut. There are fourbroad classes of opioids: naturally occurring opium alkaloids, such asmorphine (the prototypical opioid), codeine and thebaine; endogenousopioid peptides, such as endorphins; semi-synthetics such as heroine,oxycodone and hydrocodone that are produced by modifying natural opiumalkaloids (opiates) and have similar chemical structures; and puresynthetics such as fentanyl and methadone that are not produced fromopium and may have very different chemical structures than the opiumalkaloids. Additional examples of opioids are hydromorphone,oxymorphone, levorphanol, dihydrocodeine, meperidine, diphenoxylate,sufentanil, alfentanil, propoxyphene, pentazocine, nalbuphine,butorphanol, buprenorphine, meptazinol, dezocine, and pharmaceuticallyacceptable salts thereof.

The use of “hydrocodone” is meant to include a semisynthetic narcoticanalgesic and antitussive prepared from codeine with multiple actionsqualitatively similar to those of codeine. It is commonly used for therelief of moderate to moderately severe pain. Trade names includeAnexsia™, Hycodan™, Hycomine™, Lorcet™, Lortab™, Norco™, Tussionex™,Tylox™, and Vicodin™. Other salt forms of hydrocodone, such ashydrocodone bitartrate and hydrocodone polistirex, are encompassed bythe present technology.

Some embodiments of the present technology provide carboxylic acidsconjugated to hydrocodone, where the carboxylic acid group is separatedby an alkyl or alkenyl chain from the aromatic ring. The chain length ofthe alkyl or alkenyl group in some embodiments of the present technologydo not exceed two unbranched carbon atoms, for example, 2 or 1, but isnot limited in numbers of atoms on potential side-chains or additionalfunctional groups. One embodiment of the present technology includesboth carbon-only aryl, and aryl groups with heteroatoms (heteroaryl).

In some embodiments of the present technology, the aryl or heteroarylgroup, which is connected through an alkyl or alkenyl chain to thecarboxyl function, can be a 6-membered ring and contain zero or oneheteroatom. In some embodiments, additional substituted or unsubstitutedaromatic or aliphatic rings may be fused to this 6-membered aryl orheteroaryl moiety. In some embodiments of the present technology, thearyl carboxylic acids can have only one free carboxylic acid group andthe total number of phenyl substituents on the 6-membered ring can befour or less, for example 4, 3, 2 or 1.

Some embodiments of the present technology provide at least oneconjugate of hydrocodone and at least one phenylethanoic acid,phenylpropanoic acid, phenylpropenoic acid, a salt thereof, a derivativethereof or a combination thereof.

In some embodiments of the present technology at least onephenylethanoic acid, a salt thereof, a derivative thereof or acombination thereof is of formula I:

wherein,

X, Y and Z are independently selected from the group consisting of H, O,S, NH and —(CH₂)_(x)—;

R¹, R² and R³ are independently selected from the group consisting of H,alkyl, alkoxy, aryl, alkenyl, alkynyl, halo, haloalkyl, alkylaryl,arylalkyl, heterocycle, aromatic, arylalkoxy, cycloalkyl, cycloalkenyland cycloalkynyl;

o, p, q are independently selected from 0 or 1;

x is an integer between 1 and 10;

Alk is an alkyl chain —(CH₂)_(n)— wherein n is 0 or 1; and

R⁶ is H, OH or carbonyl.

Suitable phenylethanoic acids and derivatives include phenylaceticacids, including various subsets of natural products, metabolites andpharmaceuticals. One such pharmaceutical subset includes, for example,“profens”, a type of NSAIDs and derivatives of certain phenylpropionicacids (i.e., 2-methyl-2-phenylacetic acid analogs). Other suitablephenylethanoic acids and derivatives have central functions in thephenylalanine and tyrosine metabolism. Suitable phenylethanoic acids andderivatives can be found in FIG. 1 and include, but are not limited to,phenylacetic acid (hydratropic acid), 2-hydroxyphenylacetic acid,3-hydroxyphenylacetic acid, 4-hydroxyphenylacetic acid,homoprotocatechuic acid, homogentisic acid, 2,6-dihydroxyphenylaceticacid, homovanillic acid, homoisovanillic acid, homoveratric acid,atropic acid, D,L-tropic acid, diclofenac, D,L-mandelic acid,3,4-dihydroxy-D,L-mandelic acid, vanillyl-D,L-mandelic acid,isovanillyl-D,L-mandelic acid, ibuprofen, fenoprofen, carprofen,flurbiprofen, ketoprofen, and naproxen.

In other embodiments of the present technology, at least onephenylpropenoic acid, phenylpropanoic acid, a salt thereof, a derivativethereof or a combination thereof is of formula II or formula III:

wherein,

X, Y and Z are independently selected from the group consisting of H, O,S, NH and —(CH₂)_(x)—;

R¹, R² and R³ are independently selected from the group consisting of H,alkyl, alkoxy, aryl, alkenyl, alkynyl, halo, haloalkyl, alkylaryl,arylalkyl, heterocycle, aromatic, arylalkoxy, cycloalkyl, cycloalkenyland cycloalkynyl;

o, p, q are independently selected from 0 or 1;

x is an integer between 1 and 10;

R⁴ is H or OH; and

R⁵ is H, OH or carbonyl.

Suitable phenylpropanoic acids and derivatives are defined by twocarbons between the carboxyl function and the phenyl ring. Both thealkyl chain and the aryl moiety can have substituents, preferablyhydroxyl groups. Some phenylpropanoic acid and derivatives of this classcan be found in the phenylalanine metabolism. Suitable examples ofphenylpropanoic acids and derivatives are found in FIG. 2 and include,but are not limited to, benzylacetic acid, melilotic acid,3-hydroxyphenylpropanoic acid, 4-hydroxyphenylpropanoic acid,2,3-dihydroxyphenylpropanoic acid, D,L-phenyllactic acid,o,m,p-hydroxy-D,L-phenyllactic acid, and phenylpyruvic acid.

Suitable phenylpropenoic acids and derivatives include cinnamic acids(3-phenylacrylic acids) which are unsaturated analogs of benzylaceticacids. Suitable phenylpropenoic acids and derivatives occur in twoisomeric forms: cis (Z) and trans (E). In some embodiments, the isomersof the present technology are not limited to but are preferably in thetrans configuration. Similar to phenylpropanoic acids, derivatives ofcinnamic acid can be substituted on the alkenyl or aryl moiety of themolecule. In some embodiments, the substituents include, but are notlimited to, hydroxyl and methoxy groups. Suitable phenylpropenoic acidsand derivatives can be found in FIG. 3 and include, but are not limitedto, cinnamic acid, o,m,p-coumaric acid, 2,3-dihydroxycinnamic acid,2,6-dihydroxycinnamic acid, caffeic acid, ferulic acid, isoferulic acid,5-hydroxyferulic acid, sinapic acid, and 2-hydroxy-3-phenylpropenoicacid.

In another embodiment, the prodrug or hydrocodone conjugate of thepresent technology is ibuprofen-hydrocodone (Ibu-HC), which has thefollowing structure:

In another embodiment, the prodrug or hydrocodone conjugate of thepresent technology is cinnamate-hydrocodone (HC), which has thefollowing structure:

In yet another embodiment, the prodrug or conjugate composition of thepresent technology is naproxen-hydrocodone (HC), which has the followingstructure:

Some embodiments of the present technology provide a conjugate ofhydrocodone that is broken down in vivo either enzymatically orotherwise, releasing the active hydrocodone and the respective arylcarboxylic acid or metabolites thereof. The aryl carboxylic acids usedin the conjugates of the present technology are non-toxic at the givendosing levels and are preferably known drugs, natural products,metabolites, or GRAS (Generally Regarded As Safe) compounds (e.g.,preservatives, dyes, flavors, etc.) or non-toxic mimetics thereof.

Compounds, compositions and methods of the present technology providereduced potential for overdose, reduced potential for abuse or addictionand/or improve hydrocodone's characteristics with regard to hightoxicities or suboptimal release profiles. Without wishing to be limitedto the below theory, it is believed that overdose protection may occurdue to the conjugates being exposed to different enzymes and/ormetabolic pathways by oral administration where the conjugate is exposedthrough the gut and first-pass metabolism as opposed to the exposure toenzymes in the circulation or mucosal membranes which limits the abilityof hydrocodone to be released from the conjugate. Therefore, abuseresistance is provided by limiting the “rush” or “high” available fromthe active hydrocodone released by the prodrug and limiting theeffectiveness of alternative routes of administration.

The compositions of the present technology preferably have no or asubstantially decreased pharmacological activity when administeredthrough injection or intranasal routes of administration. However, theyremain orally bioavailable. Again, not wanting to be bound by anyparticular theory, the bioavailability can be a result of the hydrolysisof the chemical linkage (i.e., a covalent linkage) following oraladministration. In at least one embodiment, release of hydrocodone isreduced when the composition of the present technology is delivered byparenteral routes.

For example, in one embodiment, the composition of the presenttechnology maintains its effectiveness and abuse resistance followingthe crushing of the tablet, capsule or other oral dosage form. Incontrast, in use of nonconjugated (or “unconjugated”) forms ofhydrocodone, the hydrocodone is released immediately following crushingallowing the content of the crushed tablet to be used by injection orsnorting producing the “rush” effect sought by addicts.

In some embodiments of the present technology, the conjugates ofhydrocodone can be given orally to an animal or human patient, and, uponadministration, release the active hydrocodone by being hydrolyzed inthe body. Not to be bound by any particular theory, it is believed thatsince the aryl carboxylic acids are naturally occurring metabolites ormimetics thereof or pharmaceutically active compounds, these conjugatescan be easily recognized by physiological systems resulting inhydrolysis and release of hydrocodone. The conjugates themselves haveeither no or limited pharmacological activity as a conjugate andconsequently may follow a metabolic pathway that differs from theunconjugated drug.

In some embodiments of the present technology, the choice of suitablearyl carboxylic acids (“ligands”) to conjugate to hydrocodone determinesthe release of hydrocodone into the systemic circulation and can becontrolled even when the conjugate is administered via routes other thanoral. In one embodiment, the modified hydrocodone would releasehydrocodone similar to unconjugated or unmodified hydrocodone. Inanother embodiment, the conjugated hydrocodone releases hydrocodone in acontrolled or sustained release profile. In some embodiments, thiscontrolled release can alleviate certain side-effects and improve uponthe safety profile of the unconjugated drug. These side-effects mayinclude, but are not limited to, anxiety, bruising, constipation,decreased appetite, difficulty breathing, dizziness, drowsiness, drythroat, diarrhea, headache, nausea, stomach cramps, stomach pain, orvomiting. In another embodiment, the conjugated hydrocodone wouldselectively allow hydrocodone to be metabolized to hydromorphone. Insome embodiments, these conjugates can be used for pain relief, such asmoderate to severe pain relief.

Hydrocodone and other opioids are also highly addictive and prone tosubstance abuse. Recreational drug abuse of opioids is a common problemand usually begins with oral doses taken with the purpose of achievingeuphoria (“rush”, “high”). Over time the drug abuser often increases theoral dosages to attain more powerful “highs” or to compensate forheightened opioid tolerance. This behavior can escalate and result inexploring of other routes of administration such as intranasal(“snorting”) and intravenous (“shooting”).

In some embodiments of the present technology, the hydrocodone that isconjugated with a suitable aryl carboxylic acid ligand does not resultin rapid spikes in plasma concentrations after oral administration thatis sought by a potential drug abuser. In some embodiments, hydrocodonereleased from these conjugates has a delayed T_(max) and possibly lowerC_(max) than the unconjugated drug. Not to be bound by any particulartheory, it is believed that the conjugates of the present technologywhen taken orally or by other non-oral routes do not provide the feelingof a “rush” even when taken at higher doses but still maintain painrelief.

Additionally, in some embodiments, hydrocodone conjugated withappropriate ligands of the present technology is not hydrolyzedefficiently when administered via non-oral routes. As a result, theseconjugates do not generate high plasma or blood concentrations ofreleased hydrocodone when injected or snorted compared to freehydrocodone administered through these routes, which may be seen by alower C_(max) and/or a reduced AUC.

In some embodiments, the conjugates of the present technology, sincethey consist of covalently bound hydrocodone, are not able to bephysically manipulated to release the hydrocodone opioid from theconjugated hydrocodone by methods, for example, of grinding up orcrushing of solid forms. Further, the conjugates of the presenttechnology provide resistance to chemical hydrolysis under conditions apotential drug abuser may apply to “extract” the active portion of themolecule, for example, by boiling, or acidic or basic solution treatmentof the conjugate.

The compositions or prodrugs of the present technology can be oraldosage forms. These dosage forms include but are not limited to tablet,capsule, caplet, troche, lozenge, powder, suspension, syrup, solution ororal thin film (OTF). Preferred oral administration forms are capsule,tablet, solutions and OTF.

Solid dosage forms can include, but are not limited to, the followingtypes of excipients: antiadherents, binders, coatings, disintegrants,fillers, flavors and colors, glidants, lubricants, preservatives,sorbents and sweeteners.

Oral formulations of the present technology can also be included in asolution or a suspension in an aqueous liquid or a non-aqueous liquid.The formulation can be an emulsion, such as an oil-in-water liquidemulsion or a water-in-oil liquid emulsion. The oils can be administeredby adding the purified and sterilized liquids to a prepared enteralformula, which is then placed in the feeding tube of a patient who isunable to swallow.

Soft gel or soft gelatin capsules may be prepared, for example bydispersing the formulation in an appropriate vehicle (vegetable oils arecommonly used) to form a high viscosity mixture. This mixture is thenencapsulated with a gelatin based film using technology and machineryknown to those in the soft gel industry. The individual units so formedare then dried to constant weight.

Chewable tablets, for example, may be prepared by mixing theformulations with excipients designed to form a relatively soft,flavored, tablet dosage form that is intended to be chewed rather thanswallowed. Conventional tablet machinery and procedures, for example,direct compression and granulation, i.e., or slugging, beforecompression, can be utilized. Those individuals involved inpharmaceutical solid dosage form production are versed in the processesand the machinery used as the chewable dosage form is a very commondosage form in the pharmaceutical industry.

Film coated tablets, for example may be prepared by coating tabletsusing techniques such as rotating pan coating methods or air suspensionmethods to deposit a contiguous film layer on a tablet.

Compressed tablets, for example may be prepared by mixing theformulation with excipients intended to add binding qualities todisintegration qualities. The mixture is either directly compressed orgranulated then compressed using methods and machinery known to those inthe industry. The resultant compressed tablet dosage units are thenpackaged according to market choice, such as in unit dose, rolls, bulkbottles, blister packs, etc.

The present technology also contemplates the use ofbiologically-acceptable carriers which may be prepared from a wide rangeof materials. Without being limited, such materials include diluents,binders and adhesives, lubricants, plasticizers, disintegrants,colorants, bulking substances, flavorings, sweeteners and miscellaneousmaterials such as buffers and adsorbents in order to prepare aparticular medicated composition.

Binders may be selected from a wide range of materials such ashydroxypropylmethylcellulose, ethylcellulose, or other suitablecellulose derivatives, povidone, acrylic and methacrylic acidco-polymers, pharmaceutical glaze, gums, milk derivatives, such as whey,starches, and derivatives, as well as other conventional binders knownto persons working in the art. Exemplary non-limiting solvents arewater, ethanol, isopropyl alcohol, methylene chloride or mixtures andcombinations thereof. Exemplary non-limiting bulking substances includesugar, lactose, gelatin, starch, and silicon dioxide.

It should be understood that in addition to the ingredients particularlymentioned above, the formulations of the present technology can includeother suitable agents such as flavoring agents, preservatives andantioxidants. Such antioxidants would be food acceptable and couldinclude vitamin E, carotene, BHT or other antioxidants.

Other compounds which may be included by admixture are, for example,medically inert ingredients, e.g. solid and liquid diluent, such aslactose, dextrose, saccharose, cellulose, starch or calcium phosphatefor tablets or capsules, olive oil or ethyl oleate for soft capsules andwater or vegetable oil for suspensions or emulsions; lubricating agentssuch as silica, talc, stearic acid, magnesium or calcium stearate and/orpolyethylene glycols; gelling agents such as colloidal clays; thickeningagents such as gum tragacanth or sodium alginate, binding agents such asstarches, arabic gums, gelatin, methylcellulose, carboxymethylcelluloseor polyvinylpyrrolidone; disintegrating agents such as starch, alginicacid, alginates or sodium starch glycolate; effervescing mixtures;dyestuff; sweeteners; wetting agents such as lecithin, polysorbates orlaurylsulfates; and other therapeutically acceptable accessoryingredients, such as humectants, preservatives, buffers andantioxidants, which are known additives for such formulations.

For oral administration, fine powders or granules containing diluting,dispersing and/or surface-active agents may be presented in a draught,in water or a syrup, in capsules or sachets in the dry state, in anon-aqueous suspension wherein suspending agents may be included, or ina suspension in water or a syrup. Where desirable, flavoring,preserving, suspending, thickening or emulsifying agents can beincluded.

Liquid dispersions for oral administration may be syrups, emulsions orsuspensions. The syrups may contain as carrier, for example, saccharoseor saccharose with glycerol and/or mannitol and/or sorbitol. Inparticular a syrup for diabetic patients can contain as carriers onlyproducts, for example sorbitol, which do not metabolize to glucose orwhich metabolize only a very small amount to glucose. The suspensionsand the emulsions may contain a carrier, for example a natural gum,agar, sodium alginate, pectin, methylcellulose, carboxymethylcelluloseor polyvinyl alcohol.

Current approved formulations of hydrocodone are combination therapiesof hydrocodone and one or more other non-narcotic active ingredientdepending on intended indication. Examples of these activepharmaceuticals include, but are not limited to, acetaminophen,phenylpropanolamine, homatropine, ibuprofen, aspirin, pheniramine,chlorpheniramine, phenylephrine, pseudoephedrine, pyrilamine andguaifenesin. The conjugated hydrocodone of the present technology can beformulated with one or a combination of these or other active substancesor as standalone active ingredient without any other actives.

The conjugate compositions or prodrugs may be used in methods oftreating a patient having a disease, disorder or condition requiringbinding or inhibiting binding of an opioid to the opioid receptors ofthe patient. Treatment comprises orally administering to the patient apharmaceutically effective amount of at least one conjugate ofhydrocodone as described in the present technology. The conjugate canexhibit an improved rate of release over time, for example a slowerrelease over time and a pharmacologically effective AUC when compared toa molar equivalent amount of unconjugated hydrocodone. In otherembodiments, at least one conjugate can provide less variability in theoral PK profile when compared to a molar equivalent amount ofunconjugated hydrocodone.

In other embodiments, at least one conjugate is provided in an amountsufficient to provide a therapeutically bioequivalent AUC (area underthe curve) when compared to unconjugated hydrocodone. In furtherembodiments, the conjugate is provided in an amount sufficient toprovide a therapeutically bioequivalent AUC when compared to hydrocodonealone but does not provide a C_(max) spike in plasma or does not providean equivalent C_(max) in plasma concentrations. In some aspects, theconjugate is provided in an amount sufficient to provide atherapeutically equivalent C_(max) when compared to unconjugatedhydrocodone.

Suitable diseases, disorders or conditions that can be treated by theprodrugs or compositions of the present technology include narcoticaddiction or drug addiction and/or acute or chronic pain.

Dosages for the conjugates of the present technology depend on theirmolecular weight and the respective weight-percentage of hydrocodone aspart of the whole conjugate, and therefore can be higher than thedosages of free hydrocodone. Dosages can be calculated based on thestrengths of dosages of hydrocodone bitartrate which range between 2.5mg and 15 mg per dose. Dose conversion from hydrocodone bitartrate tohydrocodone prodrug can be performed using the following formula:dose(HC prodrug/conjugate)=[dose(HC bitartrate)×(molecular weight(HCprodrug/conjugate)/494.49)]/proportion of hydrocodone released fromprodrug/conjugate

-   -   HC: Hydrocodone

Suitable dosages of the conjugated hydrocodone of the present technologyinclude, but are not limited to, formulations including from about 0.5mg or higher, alternatively from about 2.5 mg or higher, alternativelyfrom about 5.0 mg or higher, alternatively from about 7.5 mg or higher,alternatively from about 10 mg or higher, alternatively from about 20 mgor higher, alternatively from about 30 mg or higher, alternatively fromabout 40 mg or higher, alternatively from about 50 mg or higher,alternatively from about 60 mg or higher, alternatively from about 70 mgor higher, alternatively from about 80 mg or higher, alternatively fromabout 90 mg or higher, alternatively from about 100 mg or higher, andinclude any additional increments thereof, for example, 0.1, 0.2, 0.25,0.3, 0.4, 0.5, 0.6, 0.7, 0.75, 0.8, 0.9 or 1.0 mg and multiplied factorsthereof, (e.g. ×1, ×2, ×2.5, ×5, ×10, ×100, etc). The present technologyalso includes dosage formulations including currently approvedformulations of hydrocodone (See FIG. 4), where the dosage can becalculated using the above-noted formula determined by the amount ofhydrocodone-bitartrate. The present technology provides for dosage formsformulated as a single therapy or as a combination therapy with otherAPI's (FIG. 4).

The conjugates of hydrocodone of the present technology have a number ofadvantages including, but not limited to, a reduced patient variabilityof plasma concentrations of hydrocodone or hydromorphone when comparedto free hydrocodone, reduced drug abuse potential, reduced risk ofchemical or physical manipulation resulting in full dosage ofhydrocodone released, improved dosage forms through covalent linkage tocarboxylic acids or derivatives thereof, increased or decreasedmetabolism of hydrocodone to hydromorphone and/or decreased side-effectsother than drug abuse.

In another embodiment, hydrocodone conjugates or prodrugs of the presenttechnology can produce hydrocodone and hydromorphone plasmaconcentrations that are significantly lower than respective plasmaconcentration for unconjugated Hydrocodone•BT or for other prodrugclasses when administered intranasally.

Hydrocodone is a narcotic analgesic, which acts as a weak agonist atopioid receptors in the central nervous system (CNS). It primarilyaffects the μ (mu) receptor (OP3), but also exhibits agonist activity atthe δ (delta) receptor (OP1) and κ (kappa) receptor (OP2). Additionally,hydrocodone displays antitussive properties by suppressing the coughreflex in the medullary cough center of the brain.

Side effects of opioid analgesics include gastrointestinal dysfunctioncaused by the opioids binding to the mu (μ) receptors present in thegastrointestinal tract. The side-effects in the stomach include areduction in the secretion of hydrochloric acid, decreased gastricmotility, thus prolonging gastric emptying time, which can result inesophageal reflux. Passage of the gastric contents through the duodenummay be delayed by as much as 12 hours, and the absorption of orallyadministered drugs is retarded. In the small intestines the opioidanalgesics diminish biliary, pancreatic and intestinal secretions anddelay digestion of food in the small intestine. Propulsive peristalticwaves in the colon are diminished or abolished after administration ofopioids, and tone is increased to the point of spasm. The resultingdelay in the passage of bowel contents causes considerable desiccationof the feces, which, in turn retards their advance through the colon.These actions, combined with inattention to the normal sensory stimulifor defecation reflex due to the central actions of the drug, contributeto opioid-induced constipation.

Hydrocodone is used for the treatment of moderate to moderately severepain and for inhibition of cough (especially dry, nonproductive cough).The prodrugs of the present technology may be administered for therelief of pain or for cough depression or for the treatment of anycondition that may require the blocking of opioid receptors.

The conjugates of the present technology can provide a decrease in sideeffects of the opioid analgesic, including reduced or inhibitedconstipatory effects.

The present technology also provides a method of synthesis for thepreparation of the conjugated hydrocodone of the present technology. Inone embodiment, the synthesis of the present technology includes thesteps of:

-   -   1. Protection of the ligand, if necessary;    -   2. Activation of the ligand carboxylic acid group, if not        already in activated form;    -   3. Addition of the activated ligand to hydrocodone or vice versa        in the presence of base; and    -   4. Removal of ligand protecting groups, if applicable.

If the aryl carboxylic acid contains any additional reactive functionalgroups that may interfere with the coupling to hydrocodone, it may benecessary to first attach one or more protecting groups. Any suitableprotecting group may be used depending on the type of functional groupand reaction conditions. Some protecting group examples are: acetyl(Ac), β-methoxyethoxymethyl ether (MEM), methoxymethyl ether (MOM),p-methoxybenzyl ether (PMB), trimethylsilyl (TMS),tert.-butyldimethylsilyl (TBDPS), triisopropylsilyl (TIPS),carbobenzyloxy (Cbz), p-methoxybenzyl carbonyl (Moz),tert.-butyloxycarbonyl (Boc), 9-fluorenylmethyloxycarbonyl (Fmoc),benzyl (Bn), p-methoxybenzyl (MPM), and tosyl (Ts). Temporary formationof acetals or ketals from carbonyl functions may also be appropriate.

The carboxylic acid group of the ligands should be activated in order toreact with hydrocodone and to generate appreciable amounts of conjugate.This activation can be accomplished in numerous ways by a variety ofcoupling agents. Examples of such coupling agents are:N,N′-dicyclohexylcarbodiimide (DCC),N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide (EDCI),N,N′-diisopropylcarbodiimide (DIC), 1,1′-carbonyldiimidazole (CU) orother carbodiimides;(benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate(BOP), bromotripyrrolidinophosphonium hexafluorophosphate (PyBroP),(benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate(PyBOP) or other phosphonium-based reagents;O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate(HBTU), O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumtetrafluoroborate (TBTU), fluoro-N,N,N′,N′-tetramethylformamidiniumhexafluorophosphate (TFFH),N,N,N′,N′-tetramethyl-O—(N-succinimidyl)uronium tetrafluoroborate (TSTU)or other aminium-based reagents. The aryl carboxylic acid can also beconverted to a suitable acyl halide, acyl azide or mixed anhydride.

A base may be required at any step in the synthetic scheme of an arylcarboxylic acid conjugate of hydrocodone. Suitable bases include but arenot limited to: 4-methylmorpholine (NMM), 4-(dimethylamino)pyridine(DMAP), N,N-diisopropylethylamine, lithium bis(trimethylsilyl)amide,lithium diisopropylamide (LDA), any alkali metal tert.-butoxide (e.g.,potassium tert.-butoxide), any alkali metal hydride (e.g., sodiumhydride), any alkali metal alkoxide (e.g., sodium methoxide),triethylamine or any other tertiary amine.

Suitable solvents that can be used for any reaction in the syntheticscheme of an aryl carboxylic acid conjugate of hydrocodone include butare not limited to: acetone, acetonitrile, butanol, chloroform,dichloromethane, dimethylformamide (DMF), dimethylsulfoxide (DMSO),dioxane, ethanol, ethyl acetate, diethyl ether, heptane, hexane,methanol, methyl tert.-butyl ether (MTBE), isopropanol, isopropylacetate, diisopropyl ether, tetrahydrofuran, toluene, xylene or water.

The present technology provides pharmaceutical kits for the treatment orprevention of drug withdrawal symptoms or pain in a patient. The patientmay be a human or animal patient. Suitable human patients includepediatric patients, geriatric (elderly) patients, and normativepatients. The kit comprises a specific amount of the individual doses ina package containing a pharmaceutically effective amount of at least oneconjugate of hydrocodone of the present technology. The kit can furtherinclude instructions for use of the kit. The specified amount ofindividual doses may contain from about 1 to about 100 individualdosages, alternatively from about 1 to about 60 individual dosages,alternatively from about 10 to about 30 individual dosages, including,about 1, about 2, about 5, about 10, about 15, about 20, about 25, about30, about 35, about 40, about 45, about 50, about 55, about 60, about70, about 80, about 100, and include any additional increments thereof,for example, 1, 2, 5, 10 and multiplied factors thereof, (e.g. ×1, ×2,×2.5, ×5, ×10, ×100, etc).

In one embodiment of the present technology provides cinnamate-HC, whichcould not be dosed to rats intranasally due to hydrophobic nature andinability to be solubilized in water. Not to be bound by any particulartheory, it can be assumed that this compound would also congeal orbecome clumpy when a human subject tries to inhale it intranasally(“snorting”). This property would not only make an attempt of intranasalabuse an unpleasant experience but would likely also prevent the prodrugfrom permeating the nose mucosa. As a consequence, this compound becomesineffective for this route of administration.

The presently described technology and its advantages will be betterunderstood by reference to the following examples. These examples areprovided to describe specific embodiments of the present technology. Byproviding these specific examples, it is not intended to limit the scopeand spirit of the present technology. It will be understood by thoseskilled in the art that the full scope of the presently describedtechnology encompasses the subject matter defined by the claimsappending this specification, and any alterations, modifications, orequivalents of those claims.

EXAMPLES Example 1 Chemical Stability of Conjugates of Hydrocodone

Exemplary conjugates of hydrocodone of the present technology andcontrol test conjugates not of the present technology (Adipate-HC orTyr-Tyr-Phe-Phe-Ile-hydrocodone [YYFFI-HC]) were tested for chemicalstability under conditions similar to what a potential drug abused mayuse to “extract” the active portion of the molecule, for exampledissolved in hydrochloric acid or sodium bicarbonate either at ambienttemperature or at 100° C.

Samples of conjugates of hydrocodone of the present technology weretested and compared with samples of other conjugates not of the presenttechnology for their hydrolysis to hydrocodone after dilution in 1 Nhydrochloric acid (HCl) for 1 hour at ambient temperature (˜20° C.) orin an oil bath at 100° C. The percentages indicate how much of theinitial amount of conjugate was hydrolyzed under these conditions. Theresults are shown in Table 1.

TABLE 1 1N HCl Compound ambient 100° C. Naproxen-HC 0% 33% Adipate-HC13% 100%

Samples of each conjugate were dissolved in a solution of 5% NaHCO3 forone hour at either ambient temperature (˜20° C.) or in an oil bath at100° C. The percentages indicate how much of the initial amount ofconjugate was hydrolyzed under these conditions as shown in Table 2.

TABLE 2 5% NaHCO₃ Compound ambient 100° C. Naproxen-HC 0% 8% Ibu-HC 0%22% YYFFI-HC 0% 70% Adipate-HC 3% 100%

Example 2 Oral PK Profiles of Conjugated Hydrocodone of the PresentTechnology

The PK profiles for hydrocodone or hydromorphone released from theprodrugs of the present technology can be selected to control andmodulate release to resemble various desirable curve shapes (dependingon application) while maintaining beneficial chemical, intranasal andintravenous abuse resistance.

Comparison was performed for Ibu-HC, an exemplary prodrug of the currenttechnology with Diglycolate-HC, a conjugate not within the scope of thepresent technology. Rats were orally administered the equivalent of 2mg/kg of hydrocodone freebase of the conjugate and the plasmaconcentrations of released hydrocodone and of the active metabolitehydromorphone were measured over time by LC-MS/MS. Hydrocodone plasmaconcentrations produced by Ibu-HC were higher during the initial 1-2hours than hydrocodone concentrations generated by Diglycolate-HC (AUCand C_(max) for Ibu-HC were approximately 30% and 60% higher,respectively) (See FIG. 5). Moreover, Ibu-HC generated higher plasmaconcentrations of the much more potent active metabolite hydromorphoneduring the crucial first hour (for immediate pain relief) thanDiglycolate-HC (See FIG. 6; AUC values were similar, but C_(max) forIbu-HC was approximately 155% higher). This suggests that both compoundsundergo a different metabolic pathway and potentially a greater painrelieving effect. Thus, some embodiments of the present conjugatesprovide a high initial plasma level of hydrocodone and/or hydromorphone,which may be desired for some treatments.

Example 3 Exemplary Intranasal PK Profiles of Hydrocodone Conjugates ofthe Present Technology

By selecting suitable phenylethanoic, phenylpropanoic or phenylpropenoicacid analogs the resulting hydrocodone prodrugs are not hydrolyzedefficiently when administered via routes other than oral. Prodrugs ofthe present technology with appropriately elected ligands can producehydrocodone and hydromorphone plasma concentrations that aresignificantly lower than respective plasma concentration for unboundHydrocodone•BT or for other prodrug classes when administeredintranasally.

Ibu-HC and Adipate-HC were administered to rats intranasally at dosesequivalent to 2 mg/kg of freebase hydrocodone and the plasmaconcentrations of released hydrocodone and of the active metabolitehydromorphone were measured by LC-MS/MS over time. Ibu-HC exhibitedbetter abuse protection than Adipate-HC since hydrocodone plasmaconcentrations were significantly lower for Ibu-HC (FIG. 7; AUC andC_(max) for Adipate-HC were approximately 170% and 245% higher,respectively). Moreover, Ibu-HC produced a very low plasma concentrationof hydromorphone when compared to Adipate-HC (FIG. 8; AUC and C_(max)for Adipate-HC were approximately 940% and 1,010% higher, respectively).

Example 4 Exemplary Intravenous PK Profiles of Hydrocodone Conjugates ofthe Present Technology

Some of the phenylethanoic, phenylpropanoic or phenylpropenoic acidhydrocodone conjugates or prodrugs are hydrophobic and thus poorlywater-soluble. Some hydrophobic prodrugs of the present technology havevery low water solubility, and include, but are not limited to, Ibu-HCand Cinnamate-HC. Ibu-HC and Cinnamate-HC cannot be administeredintravenously at oral equivalent doses because they cannot dissolve in apractical amount of water (injectable compounds must be completely insolution, because any solid particle may cause an embolism). The amountof water necessary to dissolve a desirable amount of conjugate wouldmake an injection unfeasible and thus make these compounds drug-abuseresistance by injection. This is in contrast to other classes ofprodrugs not encompassed in the present technology that arewater-soluble and could be dosed intravenously in rats at oralequivalent doses, including Adipate-HC and Diglycolate-HC.

Example 5 Comparison of Oral PK Profiles of Hydrocodone Conjugates

Oral PK profiles of hydrocodone conjugates were tested by administeringIbu-HC, cinnamate-HC or unconjugated Hydrocodone BT to rats at dosesequivalent to 2 mg/kg of freebase hydrocodone and measuring the plasmaconcentrations of released hydrocodone or of active metabolitehydromorphone over time. After oral administration, Ibu-HC producedhydrocodone and hydromorphone plasma concentrations that were similar tothe respective concentrations found for unconjugated Hydrocodone•BT(FIG. 9 and FIG. 10). The corresponding AUC and C_(max) values werewithin the range of bioequivalence for the same dose (based onhydrocodone freebase).

During the first hour the oral PK profile of hydrocodone released fromCinnamate-HC exhibited a somewhat larger spike when compared to theparent drug, Hydrocodone•BT (FIG. 9). However, during subsequentelimination hydrocodone plasma concentrations were similar for bothcompounds. The opposite was found for the active metabolite,hydromorphone (FIG. 10). Unlike unbound Hydrocodone•BT, oraladministration of Cinnamate-HC did not create a pronounced initial spikeof hydromorphone plasma concentrations. The concentrations of the activemetabolite produced by Cinnamate-HC remained within a relatively closerange of the C_(max) until the two hour time point. This resulted in amuch flatter PK profile of hydromorphone for Cinnamate-HC when comparedto Hydrocodone•BT.

Example 6 Intranasal PK Profiles of Hydrocodone Conjugates

The intranasal profiles of Ibu-HC were compared to the unconjugated drugHydrocodone•BT by administering to rats intranasally and measuring theplasma concentration of hydrocodone or hydromorphone over time.Hydrocodone plasma concentrations were significantly lower for Ibu-HC(FIG. 11; AUC and C_(max) for Hydrocodone•BT were approximately 300% and525% higher, respectively). Moreover, Ibu-HC produced very low plasmaconcentration of hydromorphone when compared to Hydrocodone•BT (FIG. 12;AUC and C_(max) for Hydrocodone•BT were approximately 745% and 790%higher, respectively).

Example 7 Synthesis of Conjugates of Hydrocodone

Synthesis of Cinnamic Acid Ester of Hydrocodone:

Cinnamoyl chloride (0.416 g, 2.5 mmol) was dissolved in a mixture ofchloroform (10 mL) and pyridine (3 mL). Hydrocodone free base (0.45 g,1.5 mmol) was added in small portions. The resulting solution wasrefluxed overnight while stirring. Solvents were evaporated to dryness.The resulting residue was dissolved in chloroform (150 mL), washed withaqueous sat. NaHCO₃ (60 mL×2) and 5% brine (60 mL×2). The organic layerwas dried over anhydrous Na₂SO₄ and concentrated. The residue waspurified by preparative TLC (10% methanol in dichloromethane) to give0.42 g of a brownish amorphous solid. The yield was 65.1%. (See FIG.13C)

Synthesis of Ibuprofen Ester of Hydrocodone:

To hydrocodone freebase (0.30 g, 1 mmol) in 15 mL of anhydrous THF wasadded a solution of LiHMDS in THF (1 M, 3 mL, 3 mmol) over 20 min. Themixture was stirred for 30 min. and ibuprofen succinate (0.91 g, 3 mmol)was added in one portion. The reaction was stirred for 6 hr. andsubsequently quenched with 60 mL of sat. NH₄Cl. The mixture was stirredfor 2 hr. and extracted with 150 mL of ethyl acetate. The ethyl acetatelayer was washed with sat. NH₄Cl (3×60 mL) and water (60 mL), dried overanhydrous Na₂SO₄ and concentrated. The residue was purified bypreparative TLC (7% methanol in dichloromethane). The product wasdissolved in 100 mL of ethyl acetate and washed with sat. NaHCO₃ (5×40mL) to remove most of the remaining unreacted ibuprofen. After dryingand concentrating, 170 mg (35%) of a waxy solid was obtained.

In the present specification, use of the singular includes the pluralexcept where specifically indicated.

The compositions, prodrugs, and methods described herein can beillustrated by the following embodiments enumerated in the numberedparagraphs that follow:

1. A composition comprising at least one conjugate of hydrocodone and atleast one of phenylethanoic acid, phenylpropanoic acid, phenylpropenoicacid, a salt thereof, a derivative thereof or a combination thereof.

2. The composition of paragraph 1, wherein the conjugate comprises atleast one phenylethanoic acid, a salt thereof, a derivative thereof or acombination thereof having the formula I:

wherein,

X, Y and Z are independently selected from the group consisting of H, O,S, NH and —(CH₂)_(x)—;

R¹, R² and R³ are independently selected from the group consisting of H,alkyl, alkoxy, aryl, alkenyl, alkynyl, halo, haloalkyl, alkylaryl,arylalkyl, heterocycle, aromatic, arylalkoxy, cycloalkyl, cycloalkenyland cycloalkynyl;

o, p, q are independently selected from 0 or 1;

x is an integer between 1 and 10;

Alk is an alkyl chain —(CH₂)_(n)— wherein n is 0 or 1; and

R⁶ is H, OH or carbonyl.

3. The composition of paragraph 2, wherein the phenylethanoic acid orderivative is a profen.

4. The composition of paragraph 2, wherein the phenylethanoic acid orderivative is a tyrosine metabolite.

5. The composition of paragraph 1, wherein the conjugate comprises atleast one phenylpropenoic acid, phenylpropanoic acid, a salt thereof, aderivative thereof or a combination thereof having the formula II orformula III:

wherein,

X, Y and Z are independently selected from the group consisting of H, O,S, NH and —(CH₂)_(x)—;

R¹, R² and R³ are independently selected from the group consisting of H,alkyl, alkoxy, aryl, alkenyl, alkynyl, halo, haloalkyl, alkylaryl,arylalkyl, heterocycle, aromatic, arylalkoxy, cycloalkyl, cycloalkenyland cycloalkynyl;

o, p, q are independently selected from 0 or 1;

x is an integer between 1 and 10;

R⁴ is H or OH; and

R⁵ is H, OH or carbonyl.

6. The composition of paragraph 1, wherein the conjugate comprises atleast one phenylethanoic acid or derivative selected from the groupconsisting of: phenylacetic acid (hydratropic acid),2-hydroxyphenylacetic acid, 3-hydroxyphenylacetic acid,4-hydroxyphenylacetic acid, homoprotocatechuic acid, homogentisic acid,2,6-dihydroxyphenylacetic acid, homovanillic acid, homoisovanillic acid,homoveratric acid, atropic acid, D,L-tropic acid, diclofenac,D,L-mandelic acid, 3,4-dihydroxy-D,L-mandelic acid,vanillyl-D,L-mandelic acid, isovanillyl-D,L-mandelic acid, ibuprofen,fenoprofen, carprofen, flurbiprofen, ketoprofen, naproxen, derivativesthereof and combinations thereof.7. The composition of paragraph 1, wherein the conjugate comprises atleast one phenylpropanoic acid or derivative selected from the groupconsisting of: benzylacetic acid, melilotic acid,3-hydroxyphenylpropanoic acid, 4-hydroxyphenylpropanoic acid,2,3-dihydroxyphenylpropanoic acid, D,L-phenyllactic acid,o,m,p-hydroxy-D,L-phenyllactic acid, phenylpyruvic acid, derivativesthereof and combinations thereof.8. The composition of paragraph 1, wherein the conjugate comprises atleast one phenylpropenoic acid or derivative selected from a groupconsisting of: cinnamic acid, o,m,p-coumaric acid, 2,3-dihydroxycinnamicacid, 2,6-dihydroxycinnamic acid, caffeic acid, ferulic acid, isoferulicacid, 5-hydroxyferulic acid, sinapic acid, 2-hydroxy-3-phenylpropenoicacid, derivatives thereof and combinations thereof.9. The composition of paragraph 1, wherein at least one conjugate isibuprofen-hydrocodone.10. The composition of paragraph 1, wherein at least one conjugate iscinnamate-hydrocodone.11. The composition of paragraph 1, wherein at least one conjugate isnaproxen-hydrocodone.12. A composition comprising a phenylethanoate-hydrocodone conjugate, aphenylpropanoate-hydrocodone conjugate, a phenylpropenoate-hydrocodoneconjugate, a salt thereof, a derivative thereof or a combinationthereof.13. The composition of paragraph 12, wherein the composition comprises aphenylethanoate-hydrocodone conjugate which is a conjugate ofhydrocodone and at least one phenylethanoic acid, a salt thereof, aderivative thereof or a combination thereof having the formula I:

wherein,

X, Y and Z are independently selected from the group consisting of H, O,S, NH and —(CH₂)_(x)—;

R¹, R² and R³ are independently selected from the group consisting of H,alkyl, alkoxy, aryl, alkenyl, alkynyl, halo, haloalkyl, alkylaryl,arylalkyl, heterocycle, aromatic, arylalkoxy, cycloalkyl, cycloalkenyland cycloalkynyl;

o, p, q are independently selected from 0 or 1;

x is an integer between 1 and 10;

Alk is an alkyl chain —(CH₂)_(n)— wherein n is 0 or 1; and

R⁶ is H, OH or carbonyl.

14. The composition of paragraph 12, wherein the composition comprisesat least one phenylpropanoate-hydrocodone conjugate orphenylpropenoate-hydrocodone conjugate which is a conjugate ofhydrocodone and at least one phenylpropenoic acid or phenylpropanoicacid, a salt thereof, a derivative thereof or a combination thereof offormula II or formula III:

wherein,

X, Y and Z are independently selected from the group consisting of H, O,S, NH and —(CH₂)_(x)—;

R¹, R² and R³ are independently selected from the group consisting of H,alkyl, alkoxy, aryl, alkenyl, alkynyl, halo, haloalkyl, alkylaryl,arylalkyl, heterocycle, aromatic, arylalkoxy, cycloalkyl, cycloalkenyland cycloalkynyl;

o, p, q are independently selected from 0 or 1;

x is an integer between 1 and 10;

R⁴ is H or OH; and

R⁵ is H, OH or carbonyl.

15. The composition of any one of paragraphs 1-14, wherein at least oneconjugate is a treatment or preventative composition for treatingnarcotic or opioid abuse or prevent withdrawal.

16. The composition of any one of paragraphs 1-14, wherein at least oneconjugate is a pain treatment composition.

17. The composition of any one of paragraphs 1-14, wherein at least oneconjugate is a moderate to severe pain treatment composition.

18. The composition of any one of paragraphs 1-14, wherein at least oneconjugate reduces or prevents oral, intranasal or intravenous drugabuse.

19. The composition of any one of paragraphs 1-14, wherein at least oneconjugate provides oral, intranasal or parenteral drug abuse resistance.

20. The composition of any one of paragraphs 1-14, wherein at least oneconjugate exhibits a slower rate of release over time and a higher AUCwhen compared to unconjugated hydrocodone over that same time period.

21. The composition of any one of paragraphs 1-14, wherein at least oneconjugate exhibits less variability in the oral PK profile when comparedto unconjugated hydrocodone.

22. The composition of any one of paragraphs 1-14, wherein at least oneconjugate has reduced side effects when compared with unconjugatedhydrocodone.

23. The composition of any one of paragraphs 1-14, wherein at least oneconjugate is resistant to drug tampering by either physical or chemicalmanipulation.

24. The composition of any one of paragraphs 1-14, wherein at least oneconjugate is provided in a dosage form selected from the groupconsisting of: a tablet, a capsule, a caplet, a suppository, a troche, alozenge, an oral powder, a solution, an oral film, a thin strip, aslurry, and a suspension.25. The composition of any one of paragraphs 1-14, wherein at least oneconjugate is provided in an amount sufficient to provide atherapeutically bioequivalent AUC when compared to unconjugatedhydrocodone.26. The composition of any one of paragraphs 1-14, wherein at least oneconjugate is provided in an amount sufficient to provide atherapeutically bioequivalent AUC when compared to unconjugatedhydrocodone but does not provide an equivalent C_(max).27. The composition of any one of paragraphs 1-14, wherein at least oneconjugate is provided in an amount sufficient to provide atherapeutically bioequivalent AUC when compared to hydrocodone alone,but provides a higher C_(max).28. The composition of any one of paragraphs 1-14, wherein at least oneconjugate is provided in an amount sufficient to provide atherapeutically bioequivalent AUC and C_(max) when compared tohydrocodone alone.29. The composition of any one of paragraphs 1-14, wherein at least oneconjugate is present in an amount of from about 0.5 mg or higher.30. The composition of any one of paragraphs 1-14, wherein at least oneconjugate is present in an amount of from about 2.5 mg or higher.31. The composition of any one of paragraphs 1-14, wherein at least oneconjugate is present in an amount of from about 5 mg or higher.32. The composition of any one of paragraphs 1-14, wherein at least oneconjugate is present in an amount of from about 10 mg or higher.33. The composition of any one of paragraphs 1-14, wherein at least oneconjugate is present in an amount of from about 20 mg or higher.34. The composition of any one of paragraphs 1-14, wherein at least oneconjugate is present in an amount of from about 50 mg or higher.35. The composition of any one of paragraphs 1-14, wherein at least oneconjugate is present in an amount of from about 100 mg or higher.36. The composition of any one of paragraphs 1-14, wherein at least oneconjugate exhibits less variability in the intranasal PK profile whencompared to unconjugated hydrocodone.37. The composition of any one of paragraphs 1-14, wherein at least oneconjugate exhibits less variability in the parenteral PK profile whencompared to unconjugated hydrocodone.38. The composition of any one of paragraphs 1-14, wherein at least oneconjugate exhibits less variability in the intravenous PK profile whencompared to unconjugated hydrocodone.39. A method for treating a patient having a disease, disorder orcondition requiring or mediated by binding of an opioid to the opioidreceptors of the patient, comprising orally administering to the patienta pharmaceutically effective amount of at least one conjugate ofhydrocodone and at least one of phenylethanoic acid, phenylpropanoicacid, phenylpropenoic acid, a salt thereof, a derivative thereof or acombination thereof.40. A method for treating a patient having a disease, disorder orcondition requiring or mediated by binding of an opioid to the opioidreceptors of the patient, comprising orally administering to the patienta pharmaceutically effective amount of a phenylethanoate-hydrocodoneconjugate, a salt thereof, a derivative thereof or a combinationthereof, wherein the conjugate is ibuprofen-hydrocodone.41. A method for treating a patient having a disease, disorder orcondition requiring or mediated by binding of an opioid to the opioidreceptors of the patient, comprising orally administering to the patienta pharmaceutically effective amount of a phenylpropenoate-hydrocodoneconjugate, a salt thereof, a derivative thereof or a combinationthereof, wherein the conjugate is cinnamate-hydrocodone.42. A method for treating a patient having a disease, disorder orcondition requiring or mediated by binding of an opioid to the opioidreceptors of the patient, comprising orally administering to the patienta pharmaceutically effective amount of a phenylethanoate-hydrocodoneconjugate, a salt thereof, a derivative thereof or a combinationthereof, wherein the conjugate is naproxen-hydrocodone.43. The method of any one of paragraphs 39-42, wherein at least oneconjugate binds reversibly to the opioid receptors of the patient.44. The method of any one of paragraphs 39-42, wherein at least oneconjugate binds reversibly to the opioid receptors of the patientwithout a substantial CNS depressive effect.45. The method of any one of paragraphs 39-42, wherein at least oneconjugate prevents or reduces at least one constipatory side effect ofhydrocodone alone.46. The method of any one of paragraphs 39-42, wherein at least oneconjugate exhibits reduced or prevented constipatory effects.47. The method any one of paragraphs 39-42, wherein at least oneconjugate binds irreversibly to the opioid receptors of the patient.48. The method of paragraph 47, wherein at least one conjugate bindsirreversibly to the opioid receptors of the patient without a CNSdepressive effect.49. A method for treating a patient having a disease, disorder orcondition requiring inhibiting binding of an opioid to the opioidreceptors of the patient, comprising orally administering to the patienta pharmaceutically effective amount of at least one conjugate ofhydrocodone and at least one phenylethanoic acid, phenylpropanoic acid,phenylpropenoic acid, a salt thereof, a derivative thereof or acombination thereof.50. A method for treating a patient having a disease, disorder orcondition requiring inhibiting binding of an opioid to the opioidreceptors of the patient, comprising orally administering to the patienta pharmaceutically effective amount of at least onephenylethanoate-hydrocodone conjugate, a salt thereof, a derivativethereof or a combination thereof, wherein the conjugate isibuprofen-hydrocodone.51. A method for treating a patient having a disease, disorder orcondition requiring inhibiting binding of an opioid to the opioidreceptors of the patient, comprising orally administering to the patienta pharmaceutically effective amount of at least onephenylpropenoate-hydrocodone conjugate, a salt thereof, a derivativethereof or a combination thereof, wherein the conjugate iscinnamate-hydrocodone.52. A method for treating a patient having a disease, disorder orcondition requiring inhibiting binding of the opioid receptors of thepatient, comprising orally administering to the patient apharmaceutically effective amount of at least onephenylethanoate-hydrocodone conjugate, a salt thereof, a derivativethereof or a combination thereof, wherein the conjugate isnaproxen-hydrocodone.53. The method of any one of paragraphs 49-52, wherein at least oneconjugate reversibly inhibits binding of an opioid to the opioidreceptor of the patient.54. The method of any one of paragraphs 49-52, wherein at least oneconjugate reversibly inhibits binding of an opioid to the opioidreceptor of the patient without a substantial CNS depressive effect.55. The method of any one of paragraphs 49-52, wherein at least oneconjugate prevents or reduces at least one constipatory side effect ofhydrocodone alone.56. The method of paragraph 39 or 49, wherein the conjugate comprises atleast one phenylethanoic acid, a salt thereof, a derivative thereof or acombination thereof having the formula I:

wherein,

X, Y and Z are independently selected from the group consisting of H, O,S, NH and —(CH₂)_(x)—;

R¹, R² and R³ are independently selected from the group consisting of H,alkyl, alkoxy, aryl, alkenyl, alkynyl, halo, haloalkyl, alkylaryl,arylalkyl, heterocycle, aromatic, arylalkoxy, cycloalkyl, cycloalkenyland cycloalkynyl;

o, p, q are independently selected from 0 or 1;

x is an integer between 1 and 10;

Alk is an alkyl chain —(CH₂)_(n)—, wherein n is 0 or 1; and

R⁶ is H, OH or carbonyl.

57. The method of paragraph 39 or 49, wherein the conjugate comprises atleast one phenylpropenoic acid, or phenylpropanoic acid, a salt thereof,a derivative thereof or a combination thereof having the formula II orformula III:

wherein,

X, Y and Z are independently selected from the group consisting of H, O,S, NH and —(CH₂)_(x)—;

R¹, R² and R³ are independently selected from the group consisting of H,alkyl, alkoxy, aryl, alkenyl, alkynyl, halo, haloalkyl, alkylaryl,arylalkyl, heterocycle, aromatic, arylalkoxy, cycloalkyl, cycloalkenyland cycloalkynyl;

o, p, q are independently selected from 0 or 1;

x is an integer between 1 and 10;

R⁴ is H or OH; and

R⁵ is H, OH or carbonyl.

58. The method of any one of paragraphs 39-42 and 49-52, wherein atleast one conjugate exhibits a slower rate of release over time whencompared to an equivalent molar amount of unconjugated hydrocodone overthat same time period.

59. The method of any one of paragraphs 39-42 and 49-52, wherein atleast one conjugate exhibits a reduced AUC when compared to anequivalent molar amount of unconjugated hydrocodone over that same timeperiod.

60. The method of any one of paragraphs 39-42 and 49-52, wherein atleast one conjugate exhibits less variability in the oral PK profilewhen compared to an equivalent molar amount of unconjugated hydrocodone.

61. The method of any one of paragraphs 39-42 and 49-52, wherein atleast one conjugate has reduced side effects when compared with anequivalent molar amount of unconjugated hydrocodone.

62. The method of any one of paragraphs 39-42 and 49-52, wherein atleast one conjugate is provided in a dosage form selected from the groupconsisting of: a tablet, a capsule, a caplet, a suppository, a troche, alozenge, an oral powder, a solution, an oral film, a thin strip, aslurry, and a suspension.63. The method of any one of paragraphs 39-42 and 49-52, wherein atleast one conjugate is provided in an amount sufficient to provide atherapeutically bioequivalent AUC when compared to an equivalent molaramount of unconjugated hydrocodone.64. The method of any one of paragraphs 39-42 and 49-52, wherein atleast one conjugate is provided in an amount sufficient to provide atherapeutically bioequivalent AUC and C_(max) when compared to anequivalent molar amount of unconjugated hydrocodone.65. The method of any one of paragraphs 39-42 and 49-52, wherein atleast one conjugate is provided in an amount sufficient to provide atherapeutically bioequivalent AUC when compared to an equivalent molaramount of unconjugated hydrocodone, but does not provide an equivalentC_(max).66. The method of any one of paragraphs 39-42 and 49-52, wherein atleast one conjugate is present in an amount of from about 0.5 mg orhigher.67. The method of any one of paragraphs 39-42 and 49-52, wherein atleast one conjugate is present in an amount of from about 2.5 mg orhigher.68. The method of any one of paragraphs 39-42 and 49-52, wherein atleast one conjugate is present in an amount of from about 5 mg orhigher.69. The method of any one of paragraphs 39-42 and 49-52, wherein atleast one conjugate is present in an amount of from about 10 mg orhigher.70. The method of any one of paragraphs 39-42 and 49-52, wherein atleast one conjugate is present in an amount of from about 20 mg orhigher.71. The method of any one of paragraphs 39-42 and 49-52, wherein atleast one conjugate is present in an amount of from about 50 mg orhigher.72. The method of any one of paragraphs 39-42 and 49-52, wherein atleast one conjugate is present in an amount of from about 100 mg orhigher.73. A pharmaceutical kit comprising:

a specified amount of individual doses in a package containing apharmaceutically effective amount of at least one conjugate ofhydrocodone and at least one of phenylethanoic acid, phenylpropanoicacid, phenylpropenoic acid, a salt thereof, a derivative thereof or acombination thereof.

74. The pharmaceutical kit of paragraph 73, wherein the conjugatecomprises at least one phenylethanoic acid, a salt thereof, a derivativethereof or a combination thereof having the formula I:

wherein,

X, Y and Z are independently selected from the group consisting of H, O,S, NH and —(CH₂)_(x)—;

R¹, R² and R³ are independently selected from the group consisting of H,alkyl, alkoxy, aryl, alkenyl, alkynyl, halo, haloalkyl, alkylaryl,arylalkyl, heterocycle, aromatic, arylalkoxy, cycloalkyl, cycloalkenyland cycloalkynyl;

o, p, q are independently selected from 0 or 1;

x is an integer between 1 and 10;

Alk is an alkyl chain —(CH₂)_(n)—, wherein n is 0 or 1; and

R⁶ is H, OH or carbonyl.

75. The pharmaceutical kit of paragraph 73, wherein the conjugatecomprises at least one phenylpropenoic acid, phenylpropanoic acid, asalt thereof, a derivative thereof or a combination thereof having theformula II or formula III:

wherein,

X, Y and Z are independently selected from the group consisting of H, O,S, NH and —(CH₂)_(x)—;

R¹, R² and R³ are independently selected from the group consisting of H,alkyl, alkoxy, aryl, alkenyl, alkynyl, halo, haloalkyl, alkylaryl,arylalkyl, heterocycle, aromatic, arylalkoxy, cycloalkyl, cycloalkenyland cycloalkynyl;

o, p, q are independently selected from 0 or 1;

x is an integer between 1 and 10;

R⁴ is H or OH; and

R⁵ is H, OH or carbonyl.

76. The kit of paragraph 73, 74 or 75, wherein the kit furthercomprises:

(ii) instructions for use of the kit in a method for treating orpreventing drug withdrawal symptoms or pain in a human.

77. The kit of paragraph 76, wherein the patient is a pediatric patient.

78. The kit of paragraph 76, wherein the patient is an elderly patient.

79. The kit of paragraph 76, wherein the patient is a normative patient.

80. The kit of paragraph 73, 74 or 75, wherein the individual dosagescomprise at least about 0.5 mg or higher of at least one conjugate.

81. The kit of paragraph 73, 74 or 75, wherein the individual dosagescomprise at least about 2.5 mg or higher of at least one conjugate.

82. The kit of paragraph 73, 74 or 75, wherein the individual dosagescomprise at least about 5.0 mg or higher of at least one conjugate.

83. The kit of paragraph 73, 74 or 75, wherein the individual dosagescomprise at least about 10 mg or higher of at least one conjugate.

84. The kit of paragraph 73, 74 or 75, wherein the individual dosagescomprise at least about 20 mg or higher of at least one conjugate.

85. The kit of paragraph 73, 74 or 75, wherein the individual dosagescomprise at least about 50 mg or higher of at least one conjugate.

86. The kit of paragraph 73, 74 or 75, wherein the individual dosagescomprise at least about 100 mg or higher of at least one conjugate.

87. The kit of paragraph 73, 74 or 75, wherein the kit comprises fromabout 1 to about 60 individual doses.

88. The kit of paragraph 73, 74 or 75, wherein the kit comprises fromabout 10 to about 30 individual doses.

89. The kit of paragraph 73, wherein at least one conjugate isibuprofen-hydrocodone.

90. The kit of paragraph 73, wherein at least one conjugate iscinnamate-hydrocodone.

91. A prodrug comprising a conjugate of hydrocodone and at least onephenylethanoic acid, a salt thereof, a derivative thereof or acombination thereof having the formula I:

wherein,

X, Y and Z are independently selected from the group consisting of H, O,S, NH and —(CH₂)_(x)—;

R¹, R² and R³ are independently selected from the group consisting of H,alkyl, alkoxy, aryl, alkenyl, alkynyl, halo, haloalkyl, alkylaryl,arylalkyl, heterocycle, aromatic, arylalkoxy, cycloalkyl, cycloalkenyland cycloalkynyl;

o, p, q are independently selected from 0 or 1;

x is an integer between 1 and 10;

Alk is an alkyl chain —(CH₂)_(n)—, wherein n is 0 or 1; and

R⁶ is H, OH or carbonyl.

92. A prodrug comprising a conjugate of hydrocodone and at least one ofphenylpropanoic acid, phenylpropenoic acid, a salt thereof, a derivativethereof or a combination thereof having the formula II or formula III:

wherein,

X, Y and Z are independently selected from the group consisting of H, O,S, NH and —(CH₂)_(x)—;

R¹, R² and R³ are independently selected from the group consisting of H,alkyl, alkoxy, aryl, alkenyl, alkynyl, halo, haloalkyl, alkylaryl,arylalkyl, heterocycle, aromatic, arylalkoxy, cycloalkyl, cycloalkenyland cycloalkynyl;

o, p, q are independently selected from 0 or 1;

x is an integer between 1 and 10;

R⁴ is H or OH; and

R⁵ is H, OH or carbonyl.

93. A prodrug comprising a phenylethanoate-hydrocodone conjugate, aphenylpropanoate-hydrocodone conjugate, a phenylpropenoate-hydrocodoneconjugate, a derivative thereof or a combination thereof.

94. A prodrug comprising ibuprofen-hydrocodone.

95. A prodrug comprising cinnamate-hydrocodone.

96. A prodrug comprising naproxen-hydrocodone.

The presently described technology is now described in such full, clear,concise and exact terms as to enable any person skilled in the art towhich it pertains, to practice the same. It is to be understood that theforegoing describes preferred embodiments of the technology and thatmodifications may be made therein without departing from the spirit orscope of the invention as set forth in the appended claims.

The invention claimed is:
 1. A composition comprising a conjugate,wherein the conjugate is cinnamate-hydrocodone.
 2. The composition ofclaim 1, wherein the conjugate is a treatment composition for treatingnarcotic or opioid abuse or reduces withdrawal.
 3. The composition ofclaim 1, wherein the conjugate reduces oral, intranasal or intravenousdrug abuse.
 4. The composition of claim 1, wherein the conjugate is apain treatment composition.
 5. The composition of claim 1, wherein theconjugate exhibits a slower rate of release over time and a higher AUCwhen compared to unconjugated hydrocodone over that same time period. 6.The composition of claim 1, wherein the conjugate exhibits lessvariability in the oral PK profile when compared to unconjugatedhydrocodone.
 7. The composition of claim 1, wherein the conjugate isprovided in a dosage form selected from the group consisting of: atablet, a capsule, a caplet, a suppository, a troche, a lozenge, an oralpowder, a solution, an oral film, a thin strip, a slurry, and asuspension.
 8. The composition of claim 1, wherein the conjugate isprovided in an amount sufficient to provide a therapeuticallybioequivalent AUC when compared to unconjugated hydrocodone.
 9. Thecomposition of claim 1, wherein the conjugate is provided in an amountsufficient to provide a therapeutically bioequivalent AUC and C_(max)when compared to unconjugated hydrocodone.
 10. The composition of claim1, wherein the conjugate is provided in an amount sufficient to providea therapeutically bioequivalent AUC when compared to unconjugatedhydrocodone but does not provide an equivalent C_(max).
 11. Acomposition, comprising cinnamic acid conjugated to hydrocodone whereinthe conjugate has the following structure: